Cargando…

Systematic review of outcomes and endpoints in preventive migraine clinical trials

BACKGROUND: Over the last six decades (earliest included publication from 1959), clinical trials of migraine preventive treatments have led to the regulatory approval of many medications and devices. Despite similar clinical goals, the outcomes and endpoints used in these trials are broad and not we...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGinley, James S., Houts, Carrie R., Nishida, Tracy K., Buse, Dawn C., Lipton, Richard B., Goadsby, Peter J., Dodick, David W., Wirth, R. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986733/ https://www.ncbi.nlm.nih.gov/pubmed/33600610 http://dx.doi.org/10.1111/head.14069

Ejemplares similares

Systematic review of outcomes and endpoints in acute migraine clinical trials
por: Houts, Carrie R., et al.
Publicado: (2021)

Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention
por: Lipton, Richard B., et al.
Publicado: (2022)

Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study
por: Houts, Carrie R., et al.
Publicado: (2020)

Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine
por: Houts, Carrie R., et al.
Publicado: (2020)

Content Validity of HIT‐6 as a Measure of Headache Impact in People With Migraine: A Narrative Review
por: Houts, Carrie R., et al.
Publicado: (2019)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study
por: Schwedt, Todd J., et al.
Publicado: (2018)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study
por: Buse, Dawn C., et al.
Publicado: (2020)

Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Migraine headache is present in the aura phase – a prospective study
por: Hansen, JM, et al.
Publicado: (2013)

EHMTI-0099. Migraineur perception regarding family burden from chronic migraine: results of the CAMEO (chronic migraine epidemiology & outcomes) study
por: Buse, DC, et al.
Publicado: (2014)

Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
por: Goadsby, P, et al.
Publicado: (2014)

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability
por: Lipton, Richard B., et al.
Publicado: (2016)

Treatment preferences and the selection of acute migraine medications: results from a population-based survey
por: Lipton, Richard B., et al.
Publicado: (2004)

Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post‐Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial
por: Dodick, David W., et al.
Publicado: (2018)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Major life events, stress appraisal, and migraine: results of the American Migraine Prevalence and Prevention (AMPP) study
por: Manack, AN, et al.
Publicado: (2013)

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020)

Headache-related health resource utilisation in chronic and episodic migraine across six countries
por: Sanderson, Joanna C, et al.
Publicado: (2013)

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)
por: Starling, Amaal J, et al.
Publicado: (2018)

TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points
por: Bigal, Marcelo E., et al.
Publicado: (2016)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
por: Goadsby, Peter J, et al.
Publicado: (2019)

Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM)
por: Lipton, Richard B, et al.
Publicado: (2015)

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale
por: Lipton, Richard B., et al.
Publicado: (2017)

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
por: Lipton, Richard B., et al.
Publicado: (2022)

Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial
por: Lipton, Richard B, et al.
Publicado: (2021)

The migraine postdrome: An electronic diary study
por: Giffin, Nicola J., et al.
Publicado: (2016)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Comorbid pain and migraine chronicity: The Chronic Migraine Epidemiology and Outcomes Study
por: Scher, Ann I., et al.
Publicado: (2017)

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
por: Saper, Joel R, et al.
Publicado: (2011)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches
por: Mannix, Sally, et al.
Publicado: (2016)

Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)
por: Bloudek, L. M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hmu6al6lkn7clvenje7ep7foet